Investigations of AGEs’ inhibitory and nephroprotective potential of ursolic acid towards reduction of diabetic complications
- 15 January 2022
- journal article
- research article
- Published by Springer Nature in Journal of Natural Medicines
- Vol. 76 (2) , 490-503
Abstract
In diabetes, interactions between AGEs (advanced glycation end products) and RAGEs (receptors of AGEs) are responsible for chronic complications and the current work reports the potential of ursolic acid as a RAGE inhibitor. The three-dimensional crystal structure of RAGE was first docked with target molecules by ‘AutodockVina’ using GROMOS 96 4381 parameters. Druggability and pharmacokinetic properties were calculated from the SwissADME server. In vitro bovine serum albumin (BSA)–glucose fluorescence and BSA–methylglyoxal fluorescence assays were also performed. Finally, alloxan-induced diabetic mice were administered ursolic acid and metformin standards (at 1, 50, 100 mg/kg) for 50 days. Blood glucose levels, several blood parameters, blood lipid profiles, supernatants of homogenized kidney and plasma of mice were examined. In the computational study, ursolic acid showed greater binding affinity (-7.5 kcal/mol) for RAGE with an ADMET profiles and lead-likeness compared to metformin as a standard antidiabetic. In the in vitro fluorescence assays, the IC50 value for ursolic acid was much less than that of metformin standard. During the in vivo study, significant reduction in the levels of blood glucose, HbA1C (glycated hemoglobin), creatinine, uric acid, BUN (blood urea nitrogen), AST (aspartate aminotransferase), ALT (alanine aminotransferase), ALP (alkaline phosphatase) were observed in the ursolic acid and metformin-treated mice. Substantial inhibition of AGEs’ formation in the plasma and kidney were also detected. Finally, the histopathological examinations of the kidney revealed reversal of cellular necrosis. Hence, ursolic acid is proved to be a potent AGE inhibitory agent in managing the diabetic complications. Graphical abstractKeywords
Funding Information
- JUST
This publication has 45 references indexed in Scilit:
- Inhibitory Effect of Metformin and Pyridoxamine in the Formation of Early, Intermediate and Advanced Glycation End-ProductsPLOS ONE, 2013
- Ursolic acid protects diabetic mice against monocyte dysfunction and accelerated atherosclerosisAtherosclerosis, 2011
- Inhibition of advanced glycation endproduct formation by foodstuffsFood & Function, 2011
- Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetesExperimental Gerontology, 2011
- A consistent and accurateab initioparametrization of density functional dispersion correction (DFT-D) for the 94 elements H-PuThe Journal of Chemical Physics, 2010
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreadingJournal of Computational Chemistry, 2009
- Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein‐1 (MCP‐1) levels in patients with type 2 diabetesDiabetes/Metabolism Research and Reviews, 2008
- Assessing the Minimum Number of Data Points Required for Accurate IC 50 DeterminationASSAY and Drug Development Technologies, 2005
- The Protein Data BankActa Crystallographica Section D Structural Biology, 2002
- Ab initio energy-adjusted pseudopotentials for elements of groups 13–17Molecular Physics, 1993